University of Mississippi

eGrove
Faculty and Student Publications

Pharmacy, School of

1-1-2020

Novel gastroretentive floating pulsatile drug delivery system
produced via hot-melt extrusion and fused deposition modeling
3D printing
Nagi Reddy Dumpa
University of Mississippi

Suresh Bandari
University of Mississippi

Michael A. Repka
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/pharmacy_facpubs

Recommended Citation
Reddy Dumpa, N., Bandari, S., & A. Repka, M. (2020). Novel Gastroretentive Floating Pulsatile Drug
Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing.
Pharmaceutics, 12(1), 52. https://doi.org/10.3390/pharmaceutics12010052

This Article is brought to you for free and open access by the Pharmacy, School of at eGrove. It has been accepted
for inclusion in Faculty and Student Publications by an authorized administrator of eGrove. For more information,
please contact egrove@olemiss.edu.

pharmaceutics
Article

Novel Gastroretentive Floating Pulsatile Drug
Delivery System Produced via Hot-Melt Extrusion
and Fused Deposition Modeling 3D Printing
Nagi Reddy Dumpa 1 , Suresh Bandari 1 and Michael A. Repka 1,2, *
1
2

*

Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi,
Oxford, MS 38677, USA; ndumpa@go.olemiss.edu (N.R.D.); sbandari@olemiss.edu (S.B.)
Pii Center for Pharmaceutical Innovation & Instruction, The University of Mississippi, Oxford,
MS 38677, USA
Correspondence: marepka@olemiss.edu; Tel.: +1-662-915-1155; Fax: +1-662-915-1177

Received: 5 December 2019; Accepted: 6 January 2020; Published: 8 January 2020




Abstract: This study was performed to develop novel core-shell gastroretentive floating pulsatile drug
delivery systems using a hot-melt extrusion-paired fused deposition modeling (FDM) 3D printing
and direct compression method. Hydroxypropyl cellulose (HPC) and ethyl cellulose (EC)-based
filaments were fabricated using hot-melt extrusion technology and were utilized as feedstock material
for printing shells in FDM 3D printing. The directly compressed theophylline tablet was used as the
core. The tablet shell to form pulsatile floating dosage forms with different geometries (shell thickness:
0.8, 1.2, 1.6, and 2.0 mm; wall thickness: 0, 0.8, and 1.6 mm; and % infill density: 50, 75, and 100) were
designed, printed, and evaluated. All core-shell tablets floated without any lag time and exhibited
good floating behavior throughout the dissolution study. The lag time for the pulsatile release of the
drug was 30 min to 6 h. The proportion of ethyl cellulose in the filament composition had a significant
(p < 0.05) effect on the lag time. The formulation (2 mm shell thickness, 1.6 mm wall thickness, 100%
infill density, 0.5% EC) with the desired lag time of 6 h was selected as an optimized formulation.
Thus, FDM 3D printing is a potential technique for the development of complex customized drug
delivery systems for personalized pharmacotherapy.
Keywords: hot-melt extrusion; fused deposition modeling; 3D printing; floating systems; pulsatile
release; chronotherapeutic delivery

1. Introduction
Maintaining a constant plasma drug concentration is not beneficial in all disease conditions.
Some diseases may require pulse delivery of drugs to avoid unwanted adverse effects and drug
exposure [1]. Certain diseases, such as bronchial asthma, angina pectoris, ulcers, and rheumatoid
arthritis, are regulated by the circadian rhythm of the body and require drug administration at specific
times of a day, particularly in the early morning hours. Such diseases require pulsatile drug delivery
after a lag time to improve patient compliance and drug adherence. Pulsatile drug delivery systems
(PDDS) provide a timely pharmacological effect to the patient, while preventing unwanted sustained
drug exposure. PDDS does not interrupt patients normal sleep patterns following an evening dose
of medication. Moreover, pulsatile systems can prevent detrimental drug–drug interactions without
changing the administration schedule of patients taking multiple medications at the same time and
can enhance patient compliance [2–4]. To address these issues, a drug delivery system that delivers a
pulsatile release of drugs after a pre-determined lag time is necessary. Thus, drugs administered at
bedtime would be released in the early morning hours and be available to alleviate the symptoms and
improve the quality of life of the patients.
Pharmaceutics 2020, 12, 52; doi:10.3390/pharmaceutics12010052
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Various biological factors influence the transit time of drugs in the upper gastrointestinal tract
and are a challenge to drugs that are locally active in the stomach, unstable at a high pH, or that
have poor solubility in the lower parts of the gastrointestinal tract [5–7]. A strategy to increase the
residence time of the drugs to overcome the above-mentioned drawbacks is necessary for optimal
therapeutic outcomes. Numerous strategies have been used to increase the residence time of the
dosage forms in the stomach, including mucoadhesive systems [8,9], high-density systems that sink
to the bottom of the stomach [10], swelling systems [11] and floating systems [12–14]. Among these
strategies, floating systems are considered superior as they do not interfere with the physiological
activity of the gastrointestinal tract [15]. Floating systems are further subdivided into effervescent
and non-effervescent floating systems. The effervescent systems use gas-forming agents, whereas the
non-effervescent systems are formulated with gel-forming polymers or hollow microspheres [16].
Hot-melt extrusion (HME) is a well-known technique used in the plastic, rubber, and food
industries. Over the last three decades, its use in drug delivery and research has tremendously
increased owing to the advantages associated with this technology, such as high efficiency, solvent-free,
innovative applications, and continuous manufacturing [17]. Although HME is most widely used in
the preparation of amorphous solid dispersions, it is also used in the development of many innovative
applications, such as taste masking, abuse-deterrent formulations, chronotherapeutic systems, topical
formulations, semi-solid dosage forms, and co-amorphous systems [18–22]. Recently, the interest of
researchers has shifted to additive manufacturing of pharmaceutical dosage forms where HME is
combined with three-dimensional (3D) printing.
Three-dimensional printing is a process in which digitally controlled 3D objects are produced
by the deposition of materials in a layer-by-layer manner [23]. Previously it was widely used in
automobile, robotics, aerospace, and other industries for rapid prototyping purposes. Because of
the widespread availability of commercial 3D printers and the recent FDA approval of the first
3D printed dosage form (Spritam), its use in pharmaceutical research has greatly increased [24].
The main reason for the increased attention of researchers on 3D printing is because of its potential to
create complex, customized, and personalized-on-demand dosage forms. Recently, fused deposition
modeling (FDM) 3D printing has been used in the preparation of various novel drug delivery systems,
such as personalized vaginal progesterone rings [25], channeled tablets for superior disintegration
and dissolution [26], personalized oral delivery devices [27], and topical nose-shaped device for the
treatment of acne [28].
In this study, HME technology-paired FDM 3D printing and conventional direct compression
methods were utilized to produce novel core-shell floating pulsatile tablets with a predetermined lag
time of 6 h. Asthma is a chronic inflammatory condition of the airways and symptoms of this condition
include shortness of breath, chest tightness and coughing, which are worsened at early morning hours
due to regulation of the circadian rhythm. So, theophylline, which is widely used for the symptomatic
treatment of chronic asthma, was chosen as a model drug. However, the in vivo performance of the
developed drug delivery system will be investigated in our future studies. The aim of the developed
drug delivery system is to achieve both floating characteristics and pulsatile release after the desired
lag time to improve therapy and quality of life of patients with asthma.
2. Materials and Methods
2.1. Materials
Theophylline anhydrous (≥99% pure) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Hydroxypropyl cellulose (HPC, Klucel LF) and ethyl cellulose (EC, Aqualon EC N14) were donated
by Ashland Inc. (Covington, KY, USA). Croscarmellose sodium (Ac-Di-Sol® ) and microcrystalline
cellulose (Avicel PH® 102) were provided by FMC Biopolymer (Newark, DE, USA). Magnesium
stearate was purchased from Alfa Aesar (Tewksbury, MA, USA). All other reagents and chemicals
used were of analytical grade.
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2.2. Thermogravimetric Analysis
A thermogravimetric analyzer (TGA 1-Pyris, PerkinElmer, Inc., Waltham, MA, USA) was used
to determine the thermal degradation of the polymers at the temperature employed in HME and 3D
printing techniques. The samples were loaded in aluminum pans and heated from 50 to 500 ◦ C at a rate
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Theophylline
w/w),
sodium (8% w/w), microcrystalline cellulose 4(34%
Pharmaceutics 2020, (57%
12, x FOR
PEERcroscarmellose
REVIEW
of 13 w/w)
and magnesium stearate (1% w/w) were sifted using a #30 sieve and blended using V-shell blender
® , Globe
2.5. Preparation
of the
Core Tablets
Direct Compression
(Maxiblend
Pharma,
NewbyBrunswick,
NJ, USA) for 10 min. The blended physical mixture
(175 mg) Theophylline
equivalent to(57%
100w/w),
mg of
theophyllinesodium
was compressed
into tablets using
8 mm
croscarmellose
(8% w/w), microcrystalline
cellulose
(34%round
w/w) flat
and by
magnesium
stearatepress
(1% w/w)
were sifted
using a #30Inc.,
sieve
andBrunswick,
blended using
punches
a single punch
(MCTMI,
GlobePharma
New
NJ,V-shell
USA).blender
(Maxiblend®, Globe Pharma, New Brunswick, NJ, USA) for 10 min. The blended physical mixture

2.6. 3D
Printing
of Pulsatile
Floating
(175
mg) equivalent
to 100
mg ofTablets
theophylline was compressed into tablets using 8 mm round flat
punches by a single punch press (MCTMI, GlobePharma Inc., New Brunswick, NJ, USA).

Initially, the hollow tablets were designed using Autodesk® Tinkercad™ free online software
(Autodesk,
CA, USA)
and saved
into
3D printer readable stl. format files. The stl. files were then
2.6. 3D Printing
of Pulsatile
Floating
Tablets
imported into Ultimaker Cura software (Cura version 4.0, Ultimaker,
Geldermalsen, Netherlands).
Initially, the hollow tablets were designed using Autodesk® Tinkercad™ free online software
Hot-melt extruded filaments were loaded into an FDM 3D printer (Prusa i3 3D desktop printer, Prusa
(Autodesk, CA, USAand saved into 3D printer readable stl. format files. The stl. files were then
Research,
Prague,
Republic),
which has
an version
E3D v64.0,
HotUltimaker,
End and aGeldermalsen,
0.4 mm nozzle
and the floating
imported
into Czech
Ultimaker
Cura software
(Cura
Netherlands).
tablets
were
printed.
All
the
tablets
were
designed
to
have
the
same
dimensions
(14.5
mmPrusa
diameter
Hot-melt extruded filaments were loaded into an FDM 3D printer (Prusa i3 3D desktop printer,
and 7Research,
mm height)
but
with
different
shell
thicknesses,
wall
(outer
shell)
thicknesses,
and
infill
Prague, Czech Republic), which has an E3D v6 Hot End and a 0.4 mm nozzle anddensities
the
◦ C.
(Tablefloating
1). The
tablets
were
printed
at tablets
a nozzle
temperature
190the
Thedimensions
other settings
used for
tablets
were
printed.
All the
were
designed to of
have
same
(14.5 mm
◦ C;thicknesses,
diameterwere
and as
7 mm
height)bed
buttemperature,
with different 60
shell
wall (outer
shell)
3D printing
follows:
nozzle traveling
speed,
50 thicknesses,
mm/s; layerand
height,
infill and
densities
(Table
1). The50
tablets
were printed at a nozzle temperature of 190 °C. The other settings
0.10 mm;
printing
speed,
mm/s.
usedstructural
for 3D printing
were as follows:
bed temperature,
60 °C; altered
nozzle traveling
50 mm/s;were
layer shell
The
parameters
of a dosage
form that were
in FDMspeed,
3D printing
height, 0.10 mm; and printing speed, 50 mm/s.
thickness, wall thickness (outer shell) and infill density. The shell can be defined as the total width
The structural parameters of a dosage form that were altered in FDM 3D printing were shell
of the perimeter of the dosage form, whereas the wall was a part of the shell that had different infill
thickness, wall thickness (outer shell) and infill density. The shell can be defined as the total width of
patterns
compact
structures
compared
to the
core.
Alteration
in thethat
infill
changes
the and
perimeter
of the
dosage form,
whereas
the inner
wall was
a part
of the shell
haddensity
different
infill the
porosity
of
the
structure
of
the
dosage
form.
The
wall
has
the
same
composition
as
that
of
the shell,
patterns and compact structures compared to the inner core. Alteration in the infill density changes
but the
is different
from
the shell.
Firstly,
HPC
filaments
were as
used
theprinting
porosity pattern
of the structure
of the
dosage
form. The
wallpure
has the
same
composition
thattoofprint
the the
shell,
but the
printing
pattern isshell
different
from the(0.8,
shell.1.2,
Firstly,
pure2.0
HPC
filaments
wereinused
to 2A.
hollow
tablets
with
four different
thicknesses
1.6, and
mm)
as shown
Figure
print the
tablets
with release
four different
shell
thicknesses
(0.8,for
1.2,floating
1.6, andtablets
2.0 mm)
shown
in and
To tassess
the hollow
lag time,
in vitro
studies
were
conducted
ofasplain
HPC
2A. To assess
the lag time,ofinethyl
vitro release
studies
were
for floating
plain
HPC Figure
with different
concentrations
cellulose
(0.5 to
10 conducted
w/w %). Secondly,
to tablets
assess of
the
effect of
HPC
and
HPC
with
different
concentrations
of
ethyl
cellulose
(0.5
to
10
w/w
%).
Secondly,
to
assess
wall thickness and % infill density of the shell on the drug release profiles, tablets with three different
the effect of wall thickness and % infill density of the shell on the drug release profiles, tablets with
wall thickness (outer shell) (0, 0.8, and 1.6 mm) as shown in (Figure 2B), and three different % infill
three different wall thickness (outer shell) (0, 0.8, and 1.6 mm) as shown in (Figure 2B), and three
densities (50, 75, and 100) as shown in (Figure 2C) were printed using the filament containing 0.5% EC.
different % infill densities (50, 75, and 100) as shown in (Figure 2C) were printed using the filament
The impact
of infill
can
only be
assessed
without
a wall.
So, a wall
thickness
of 0So,
mma was
containing
0.5%density
EC. The
impact
of infill
density
can only
be assessed
without
a wall.
wall used
whilethickness
printingofthe
tablets
infillthe
densities.
0 mm
was with
used different
while printing
tablets with different infill densities.

Figure
2. Graphical
images
thefloating
floatingtablets
tablets with
thickness
(A),(A),
wallwall
thickness
(B), (B),
Figure
2. Graphical
images
of of
the
withdifferent
differentshell
shell
thickness
thickness
and infill
density
and infill
density
(C).(C).

Pharmaceutics 2020, 12, 52

5 of 13

2.7. Loading Capacity and Buoyancy of the 3D Printed Floating Tablets
The printed tablets should remain buoyant in the gastric fluid in the stomach until the pulse
release of the drugs occurs. Theoretically, an object can float when the buoyancy force exerted by the
fluid is more than the opposite force by gravity (Archimedes’ principle), i.e., if the total force acting
vertically on the object is positive. To attain this, the total density of the dosage form should be less than
the density of the gastric contents (reported as ~1.004 g/mL) [1]. Based on this principle, the maximum
amount of the drug that can be loaded in the proposed floating system and can remain buoyant in the
gastric fluid was calculated.
2.8. In Vitro Floating Study and Refloating Ability
The in vitro floating study of the 3D printed floating tablets was performed using a United States
Pharmacopeia (USP II) dissolution test apparatus (Hanson SR8-plus™; Hanson Research, Chatsworth,
CA, USA). The media was 900 mL of 0.1 N HCl maintained at 37 ± 0.5 ◦ C and the paddle speed was
set at 50 rpm. To determine the re-floating ability of the printed tablets, tablets were immersed in
the dissolution medium for 5 s per hour using a glass rod during the floating study. The test was
performed in triplicate. To obtain clear images of the floating tablets, the tablets were transferred to
500 mL glass beakers filled with the dissolution media and the photographs were captured at 0, 2, 4,
and 6 h [29,30].
2.9. Scanning Electron Microscopy (SEM)
The surface morphology of the extruded filaments and 3D printed floating tablets were studied
with a JOEL JSM 5610LV scanning electron microscope (SEM) (JOEL, Peabody, MA, USA) with an
accelerating voltage of 5 kV. All the samples were placed on the SEM stubs and adhered by using
double-adhesive tape. The samples were sputter-coated with gold under an argon atmosphere using a
Hummer 6.2 Sputter Coater (Ladd Research Industries, Williston, VT, USA) prior to imaging.
2.10. In Vitro Drug Release Study
The drug release characteristics of the 3D printed floating tablets were determined using a
United States Pharmacopeia (USP II) dissolution test apparatus (Hanson SR8-plus™; Hanson Research,
Chatsworth, CA, USA). The dissolution media was 900 mL of 0.1 N HCl maintained at 37 ± 0.5 ◦ C,
and the paddle speed was set at 50 rpm (29). The samples were collected at the pre-determined time
intervals and analyzed for drug content using a UV/VIS spectrophotometer (GENESYS 180, Thermo
Scientific) at a wavelength of 272 nm. The calibration curve of y = 0.0556x + 0.008 was acquired with
an r2 value of 0.9996. Each test was carried out in triplicate and the collected data were plotted as
percentage cumulative drug release versus time.
2.11. Statistical Analysis
Statistical analysis was performed by one-way analysis of variance (ANOVA) with
Student-Newman-Keuls post-hoc testing using GraphPad Prism 5 software (GraphPad Software,
San Diego, CA, USA) with p ≤ 0.05 as the level of significance.
3. Results and Discussion
3.1. Thermal Analysis of the Polymers
The thermal degradation behaviors of HPC and EC are analyzed using thermogravimetric analyzer.
From the results and literature reports, it was observed that the percentage loss in the mass was <1%
at the temperature (190◦ C) used for 3D printing of the tablets [31]. A significant mass loss of the
polymers was observed at temperatures >250 ◦ C, implying that the polymers were stable during the
HME and 3D printing processes.
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3.2. Filament Preparation and Characterization
Different pharmaceutical-grade polymers were recently investigated for FDM 3D printing of the
tablets for various applications. From the available pharmaceutical-grade polymers suitable for FDM
3D printing [27,29], HPC was utilized for the preparation of domperidone sustained release intragastric
floating tablets. In this study, HPC was chosen for fabrication of the filaments required as feedstock
materials for the development of 3D printed floating pulsatile tablets. In the preliminary studies, EC
was added at different concentrations (10%, 5%, 2.5%, and 1%) to HPC to prolong the lag time for
the pulsatile drug release characteristics. After all the EC concentrations were studied, the lag time
observed was >8 h. The developed tablets with 0.5% EC exhibited a desired lag time of 6 h.
During the HME process, the filaments exiting the extruder die were coiled in irregular shapes
and were difficult to process through the 3D printer. Therefore, a conveyor belt was used to straighten
the filaments for easy loading into the 3D printer. After solidification, the filaments were coiled and
stored in a desiccator to prevent moisture uptake. The filaments that absorbed moisture became soft
and squeezed between the feeding gears of the 3D printer. This is because, after moisture absorption,
the flexibility of the filaments increased, preventing the melted material from pushing through the
heater. Further, the inflow of materials from the printer nozzle was irregular.
After fabrication of the filaments using the HME technique, the mechanical properties of these
extruded filaments were tested using a texture analyzer and compared with those of the commercially
available polylactic acid (PLA) filaments, which have optimum mechanical properties suitable for
FDM 3D printing. For a filament to be considered suitable for FDM 3D printing, it should not either
break or be curved aside by the feeding gears during the feeding process because this might result in
an inadequate flow of materials through the nozzle. If the filament is too brittle it may get broken by
the gears and if it is too flexible it may curve away from the feeding gears because the materials cannot
be pushed through the narrow 0.4 mm nozzle of the 3D printer. For this reason, there should be a
balance between the brittleness and the flexibility of the filaments.
Even though PLA is considered as a reference material for comparing the mechanical properties
of the filaments in 3D printing, it is interesting to note that filaments with a lower stiffness (breaking
stress and force) than the PLA filament were good enough for the FDM 3D printing process. This may
be due to a variation in the force applied by the gears of the different 3D printers during feeding of the
filaments into the 3D printer. In this study (Figure 3), the force required to create a 35% deformation
in the shape of the filament was considered as the maximum force that the filaments could withhold
during the feeding process without any breaking or squeezing phenomenon in the feeder. Pure HPC
and HPC + EC require a lower force of 8500 g and 7409 g, respectively, as compared to that of the
reference material PLA (25,630 g). However, these filaments did not show any breaking or squeezing
problems during the printing process, which resulted in the fabrication of high-quality floating tablets.
In a study conducted by Chai et al. [29], the authors developed intragastric sustained release
floating tablets of domperidone using HPC EXF as matrix polymer for the fabrication of filaments.
The authors used 10% (w/w) domperidone in the filament composition. The fabricated filaments
exhibited the desired mechanical properties suitable for FDM 3D printing. Similar results were
observed in the current study. In the earlier study, filaments fabricated using HPC EF and HPC HF
grades with 30% paracetamol were not suitable for FDM 3D printing [32]. The filaments produced
using both HPC EF and HPC HF were too soft. This may be due to the relatively high drug load of 30%
(w/w) paracetamol, which acted as a plasticizer and softened the filaments. These studies indicate the
significance of drug loading and the properties of drugs in the fabrication of filaments to be utilized in
FDM 3D printing.
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Figure 3. Force values of stiffness test of the hot-melt extruded filaments (error bars represent mean
± S.D).
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Table 1. Physical properties of the 3D printed floating tablets.
Filament 1 (100% (w/w) HPC)
Shell Thickness
(mm)

Wall Thickness
(mm)

Infill Density
(%)

Weight
(mg)

Density
(mg/mm3 )

Floating Duration
(h)

0.8 mm
1.2 mm
1.6 mm
2.0 mm

0.8 mm
0.8 mm
0.8 mm
0.8 mm

100
100
100
100

633.13 ± 11.20
774.67 ± 12.06
868.67 ± 18.72
1088.66 ± 7.37

0.55 ± 0.01
0.67 ± 0.01
0.75 ± 0.02
0.94 ± 0.01

1.50 ± 0.21
3.00 ± 0.16
3.50 ± 0.08
4.00 ± 0.12

Filament 2 (0.5%EC (w/w), 99.5% HPC)
Shell Thickness
(mm)

Wall Thickness
(mm)

Infill Density
(%)

Weight
(mg)

Density
(mg/mm3 )

Floating Duration
(h)

1.6 mm
0.8 mm

100
100

1086.33 ± 6.66
1080.67 ± 10.69

0.94 ± 0.01
0.93 ± 0.01

6.00 ± 0.09
5.00 ± 0.13

0.0 mm

100
75
50

1080.00 ± 16.82
902.33 ± 8.39
648.67 ± 9.87

0.93 ± 0.01
0.78 ± 0.01
0.56 ± 0.01

4.50 ± 0.26
2.00 ± 0.22
0.50 ± 0.19

2.0 mm

3.5. Loading Capacity and Buoyancy of the 3D Floating Tablets
For a tablet to remain buoyant in the gastric fluid [1],
FBuoyancy ≥ FGravity .

(1)

Equation (1) above can also be represented as follows:
ρL·Vmax g ≥ (ms + mt ) g

(2)

where ρL is the density of gastric fluid, Vmax is the maximum volume of liquid displaced (i.e., the
volume of floating pulsatile tablet, Vt ), g is the acceleration due to gravity, ms is the mass of shell, and
mt is the mass of the compressed tablet. Equation (2) is simplified as Equation (3):
ρL·Vt ≥ (ms + mt ),

(3)

where ρL is the density of the gastric fluid i.e., 1 g/cm3 , and mass of shell (ms ) + mass of compressed
tablet (mt ) is the total mass of the floating tablet (Mt ). So, Equation (3) was further simplified as
Equation (4) as follows:
(ρL·Vt ) − ms ≥ mt .
(4)
The volume of the floating tablet (Vt ) can be calculated from its dimensions. The optimized
floating tablet shell had a weight of 913 mg and a volume of 1155 mm3 . So, the maximum weight of the
compressed core tablet that can be accommodated was 242 mg. In our study, we used a compressed
core tablet with a total weight of 175 mg, which is equivalent to 100 mg of theophylline. By optimizing
the composition of the core compressed tablets for an immediate-release profile, any drug that is a
suitable candidate for a floating pulsatile release system can be delivered with this proposed pulsatile
floating tablet.
3.6. Floating and Refloating Abilities of the Printed Tablets
All the tablets placed in the dissolution media floated immediately without any lag time.
The floating ability of the printed tablets was highly correlated with their density as reported in the
previous literature [28]. Tablets with a density of >1 mg/mm3 sunk to the bottom of the dissolution
vessels. The density of the printed tablets ranged from 0.548−0.941 mg/mm3 . Tablets with high shell
thickness and high infill had higher densities. No difference in the density was observed between
the tablets with various wall thicknesses with 100% infill density (p < 0.005). When the tablets were
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3.8. In Vitro Dissolution Study
3.8. In Vitro Dissolution Study
The dissolution behavior of the 3D printed floating tablets is shown in Figure 7. From the
The dissolution behavior of the 3D printed floating tablets is shown in Figure 7. From the
dissolution data, it was observed that both the tablet geometry and addition of EC into HPC had
dissolution data, it was observed that both the tablet geometry and addition of EC into HPC had a
a significant effect on the drug release profiles (p < 0.05). The tablets with higher shell thicknesses
significant effect on the drug release profiles (p < 0.05). The tablets with higher shell thicknesses had
had integrity for a longer period of time before the pulse release of API into the dissolution media as
integrity for a longer period of time before the pulse release of API into the dissolution media as
compared to tablets with a lower thickness (Figure 7A). The tablets with a shell thickness of 2.0 mm

media into the core for a longer time. The addition of EC to the formulation increased the threshold
time for complete drug release (Figure 7B). The tablets with 2.0 mm shell thickness, which had an EC
of 0.5%, showed pulse release at the end of 5 ± 0.13 h.
To assess the effect of the wall thickness and infill density of shell on the pulse release of drug,
tablets
with three different wall thicknesses (0.0, 0.8, and 1.6 mm) and three infill densities10were
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To assess the effect of the wall thickness and infill density of shell on the pulse release of drug,
tablets with three different wall thicknesses (0.0, 0.8, and 1.6 mm) and three infill densities were
studied (50%, 75%, and 100%). The tablets with higher wall thicknesses prevented the entry of the
dissolution media more effectively than those with low wall thicknesses. This is attributed to the
closed, compact structure of the wall. This observation was consistent with the results of a previous
study [34]. The tablets with 100% infill densities demonstrated pulse release at the end of 4.5 ± 0.26 h,
followed by 75% infill (2 ± 0.22 h), and 50% infill (0.5 ± 0.19) (Figure 7C). The higher porosity of lower
infill density has a higher surface area and allows easy entry of the dissolution media into the core,
resulted in a faster release of API. Yang et al. [35] and Chen et al. [36], who used FDM 3D printing
for the development of controlled release dosage forms, reported that a higher fill density caused a
reduction in the total surface area and resulted in slower drug release from the dosage forms.
All the prepared floating tablets exhibited a pulse release of drug with different threshold times
varying from 30 min to 6 h. The tablets with a specific geometrical structure (2 mm shell, 1.6 mm wall,
100% infill) with 0.5% EC (Figure 7D) were considered optimized formulations for pulsatile release of
drugs after 6 h for effective chronotherapeutic treatment of asthma.
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4. Conclusions
Floating pulsatile tablets with the desired lag time for pulse release of theophylline were
successfully developed with the proposed HME coupled 3D printing technique. The geometrical
properties of the tablets (shell and wall thickness and infill density) and EC showed significant (p < 0.05)
effect on the lag time. Thus, the lag time can be varied from 30 min to 6 h based on the requirements.
The proposed floating pulsatile system showed high potential to deliver drugs that need high residence
time in the stomach and the pulsatile release of theophylline. This strategy reduces unwanted adverse
effects and improves patient compliance. In addition, thermolabile drugs can be delivered through this
system as the inner core tablet is not exposed to high temperatures involved in the FDM 3D printing
process. In conclusion, HME coupled 3D printing is a novel technique to develop low-cost customized
drug dosage forms for personalized pharmacotherapy. However, dosage forms fabricated using FDM
3D printing technology need to overcome the challenges in terms of regulatory concerns. Therefore,
these floating systems need to be further assessed in in vivo conditions to demonstrate their suitability
for patient use.
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